NuCana (NCNA)
(Delayed Data from NSDQ)
$3.40 USD
+0.04 (1.19%)
Updated Aug 13, 2024 03:49 PM ET
After-Market: $3.32 -0.08 (-2.35%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
NuCana PLC Sponsored ADR [NCNA]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
NUC-3373 Initial Metastatic Colorectal Cancer Phase 1b Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Acelarin Phase 1b Data Unimpressive; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
NUC-3373 and NUC-7738 Trials Resume Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 NuTide:121 Resumes Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Incrementally Positive Acelarin Data; 2019 Financials; Reiterate Buy; Modulating PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Deprioritizing PROC Looks Smart, From Our Vantage Point; 3Q19 Financials Reported
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Acelarin Phase 3 Front-Line Biliary Tract Cancer Program Could Support Accelerated Approval.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Acelarin Pancreatic Cancer Trial Discontinuation Non- Impactful, From Our Vantage Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NuCana PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Giving Nucleoside Analogs a Shot of Nitrous; Initiating at Buy and $20 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|